A new publication

We are happy to share our this new publication which was the result of a fruitful collaboration between our group and Kjersti Flatmark's team.  We here report about a vaccine solution for patients suffering Pseudomyxoma peritonei (PMP). We thank Helse Sør Øst (#2019004) for the support.

 

Abstract

Background Pseudomyxoma peritonei (PMP) is a rare, slow-growing abdominal cancer with no efficacious treatment options in non-resectable and recurrent cases. Otherwise, rare activating mutations in the GNAS oncogene are remarkably frequent in PMP and the mutated gene product, guanine nucleotide-binding protein α subunit (Gsα), is a potential tumor neoantigen, presenting an opportunity for targeting by a therapeutic cancer vaccine.

 
Page visits: 29